Rapid-progressing progressive multifocal leukoencephalopathy in two patients newly diagnosed with HIV: case series and review of literature

被引:0
作者
Barbara Badura
Szymon Barczak
Tomasz Mikuła
Alicja Wiercińska-Drapało
机构
[1] Medical University of Warsaw,Students’ Scientific Society of the Department of Infectious and Tropical Diseases and Hepatology
[2] Medical University of Warsaw,Department of Infectious and Tropical Diseases and Hepatology
[3] Warsaw’s Hospital for Infectious Diseases,undefined
来源
Journal of NeuroVirology | 2023年 / 29卷
关键词
HIV; AIDS; PML; Focal neurologic signs; JCPyV; Rapid progression;
D O I
暂无
中图分类号
学科分类号
摘要
The JC Polyomavirus (JCPyV) is a virus of global distribution and is usually kept under control by the immune system. In patients with AIDS, a latent JCPyV infection can reactivate and develop into progressive multifocal leukoencephalopathy (PML). Around half of the patients with PML die within 2 years since the diagnosis, yet in rare cases, the disease advances significantly quicker and seems to be insusceptible to any medical actions. In our clinic, we observed two cases of such course in HIV-positive patients in the AIDS stage. On admission, both patients had mild neurological symptoms such as dizziness, vision disturbances, and muscle weakness. Both had extremely low CD4 lymphocyte count (7 cells/μL, 40 cells/μL) and high HIV-1 viral load (VL) (50,324 copies/ml, 78,334 copies/ml). PML was confirmed by PCR for JCPyV DNA in cerebrospinal fluid (CSF) coupled with clinical and radiological features. Despite receiving though antiretroviral (ARV) treatment paired with intra-venous (IV) steroids, the disease progressed rapidly with neurological manifestations exacerbating throughout the few weeks following the admission. Eventually, both patients developed respiratory failure and died within less than 3 months after the onset of the neurological symptoms. Even though such curse of the disease is not common, it should be a warning to all how deadly both PML and AIDS can be and remind doctors to offer testing even to asymptomatic patients.
引用
收藏
页码:8 / 14
页数:6
相关论文
共 76 条
[1]  
Berger JR(2013)PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section Neurology 80 1430-1438
[2]  
Aksamit AJ(1998)Progressive multifocal leukoencephalopathy in patients with HIV infection J Neurovirol 4 59-68
[3]  
Clifford DB(2013)Progressive multifocal leukoencephalopathy in an immunocompetent patient J Neurol Sci 326 107-110
[4]  
Davis L(2011)Progressive multifocal leukoencephalopathy as an AIDS-defining condition in a patient with high CD4+ T-lymphocyte count Rev Soc Bras Med Trop 44 119-121
[5]  
Koralnik IJ(2012)JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy J Cell Physiol 227 3511-965
[6]  
Sejvar JJ(2020)Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration Neurotherapeutics 17 955-83
[7]  
Berger JR(2009)Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study J Infect Dis 199 77-396
[8]  
Pall L(2021)Acquired immune deficiency syndrome (AIDS) and late presentation in Poland – data from Test and Keep in Care (TAK) Polska project HIV Med 22 387-64
[9]  
Lanska D(2019)Progressive multifocal leukoencephalopathy: current insights Degenerative Neurological and Neuromuscular Disease 9 109-889
[10]  
Whiteman M(2019)Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med 380 1667-1541